FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

45 results

anthim
(obiltoxaximab)
Elusys Therapeutics, Inc.
Usage: ANTHIM is indicated for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis in adults and pediatric patients when alternative therapies are unavailable or inappropriate. It must be used with antibacterial drugs and should only be given when benefits outweigh risks of hypersensitivity or anaphylaxis.
avycaz
(ceftazidime, avibactam)
Allergan, Inc.
Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).
besivance
(Besifloxacin)
Bausch & Lomb Incorporated
Usage: BESIVANCE (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible bacteria, including Haemophilus influenzae and various Staphylococcus, Streptococcus, and Moraxella species. Efficacy for some organisms was studied in fewer than 10 infections.
beyfortus
(nirsevimab)
Sanofi Pasteur Inc.
Usage: BEYFORTUS is indicated for preventing Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season, and in children up to 24 months who are vulnerable to severe RSV disease during their second RSV season.
complera
(emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
Gilead Sciences, Inc.
Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
cresemba
(isavuconazonium sulfate)
Astellas Pharma US, Inc.
Usage: CRESEMBA is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients. It is available as an injection for patients aged 1 year and older, and as capsules for those aged 6 years and older who weigh at least 16 kg.
dalvance
(Dalbavancin)
Allergan, Inc.
Usage: DALVANCE® is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatrics caused by specific Gram-positive bacteria, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus, and various Streptococcus and Enterococcus species. Usage should target infections caused by susceptible strains to minimize resistance.
delstrigo
(doravirine, lamivudine, and tenofovir disoproxil fumarate)
Merck Sharp & Dohme LLC
Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.
descovy
(emtricitabine and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
dificid
(fidaxomicin)
Merck Sharp & Dohme LLC
Usage: DIFICID® is indicated for treating Clostridioides difficile-associated diarrhea (CDAD) in adults and children aged 6 months and older. It should be used only for infections proven or strongly suspected to be caused by C. difficile to reduce drug-resistant bacteria development.

Infectious Diseases drugs

anthim

avycaz

besivance

beyfortus

complera

cresemba

dalvance

delstrigo

descovy

dificid